

Otsuka's Economic and Health Impact in New Jersey


Otsuka is a leader in pharmacological treatments for mental health and nephrology, developing and commercializing medicines and digital healthcare solutions to address unmet needs. The company employs nearly 2,000 people in the United States.

In New Jersey, Otsuka employs 660 people at corporate offices in Princeton. Beyond its direct employment and spending, Otsuka's operations support additional jobs, wages, and economic activity in the state. In 2020, Otsuka supported nearly 3,800 jobs, generated \$312.1 million in labor income (a measure of wages), and contributed \$1.4 trillion in economic output in New Jersey. Otsuka's business activities in New Jersey also result in additional tax revenues. In 2020, state and federal tax receipts attributable to or supported by Otsuka's economic activity in New Jersey are estimated at \$131.4 million. (See Figure 1.)¹

ABOUT OTSUKA

Founded in Japan in 1921, Otsuka Pharmaceutical Co. Ltd. today has an international network of 183 companies and more than 45,000 employees in 28 countries and regions. The company has two US pharmaceutical subsidiaries, Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc.

Figure 1. Otsuka's Economic and Fiscal Impact in New Jersey



¹ These estimates were derived by Matrix Global Advisors (MGA) using a macroeconomic model of the state of New Jersey constructed by IMPLAN. A description of the methodology as well as full results of Otsuka's economic impact in the United States are available at www.getmga.com/wp-content/uploads/2022/06/Otsuka-Impact-Report_June-2022.pdf.



Otsuka's Products and Therapeutic Areas of Focus



NEUROSCIENCE

In the US, 1 in 25 people has a serious mental illness.¹ In Otsuka's 30 years of experience working in the central nervous system (CNS) therapeutic area, the company has remained committed to patients living with schizophrenia, major depressive disorder, bipolar disorder, and other CNS conditions.



OAPI co-promotes REXULTI with H. Lundbeck, A/S



OAPI co-promotes ABILIFY MAINTENA with H. Lundbeck, A/S



NEPHROLOGY

An estimated 15 percent of Americans have chronic kidney disease.² For more than 20 years, Otsuka has brought its research and expertise to this therapeutic area, focusing on developing novel drugs in areas of unmet need. Otsuka's long-term perseverance has led to major breakthroughs.

Combination of pharmacotherapies and digital medicine



Medication is only one element of a patient's complete care package

Otsuka continuously evaluates how its digital healthcare technology can provide ongoing support to patients, caregivers, and healthcare providers

Please see FULL PRESCRIBING INFORMATION including BOXED WARNING(S) for REXULTI, ABILIFY MYCITE, ABILIFY, ABILIFY MAINTENA, JYNARQUE, and SAMSCA at www.otsuka-us.com/products.



DIGITAL INNOVATION

Digital technology is changing the face of healthcare. Otsuka is at the forefront, creating novel solutions that help address the challenges of those living with serious mental illness. Otsuka believes its investment and leadership in digital health will revolutionize patient care as we know it.



² Centers for Disease Control (CDC), "About Mental Health," www.cdc.gov/mentalhealth/learn/index.htm.

³ CDC, "Chronic Kidney Disease in the United States, 2021," www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html.



We defy limitation, so that others can too.